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Coal Tar and Paving Products
The National Institute for Occupational
Safety and Health (NIOSH) has a partner-
ship relationship with the asphalt paving
and roofing industries and their associated
unions. Our partners saw in the EHP Focus
article “Paving Paradise: The Peril of
Impervious Surfaces” (Frazer 2005) the
statement on page A459: “Asphalt is one
concern, as it contains coal tar pitch, a
recognized human carcinogen .... ” Our
partners asked us if we could help them
address this statement. 
By definition, asphalt is a petroleum
product and contains no coal tar. How-
ever, some pavement-repair products and
sealants may contain coal tar. NIOSH did
not find any evidence of coal tar in U.S.
asphalt in our hazard review Health Effects
of Occupational Exposure to Asphalt
(NIOSH 2000.
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cial interests.
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Editor’s note: The following erratum was
published in the January 2006 issue (Environ
Health Perspect 114:A21):
EHP regrets the incorrect and uninten-
tional inference in “Paving Paradise: The
Peril of Impervious Surfaces” [Environ
Health Perspect 113:A456–A462 (2005)]
that coal tar pitch is used in the actual hot-
mix asphalt used to pave roads. Coal tar
pitch is instead used in many sealcoat formu-
lations used atop asphalt pavement. Findings
published in the 1 August 2005 issue of
Environmental Science & Technology sug-
gest, in fact, that coal tar-based parking lot
sealant may be a major contributor to stream
loads of polycyclic aromatic hydrocarbons,
including many known carcinogens.
Organic Diets and 
Children’s Health
In their article “Organic Diets Significantly
Lower Children’s Dietary Exposure to
Organophosphorus Pesticides,” Lu et al.
(2006) used language that is likely to be
misused by organic food marketers to pro-
mote high-priced foods and could discour-
age lower-income parents from providing
their children with a diet rich in fruits and
vegetables. 
Regarding their findings that children’s
median urinary concentrations of two
organophosphorus (OP) pesticides dropped
to nondetectable levels within 24–48 hr
after switching to an organic diet, Lu et al.
(2006) state in the “Abstract” that “an
organic diet provides a dramatic and imme-
diate protective effect against exposures”
and that these results provide “evidence of
the effectiveness of this intervention.” Later
in their article, they admit that they “did
not collect health outcome data in this
study,” but they claim that 
It is intuitive to assume that children whose diets
consist of organic food items would have a lower
probability of neurologic health risks, a common
toxicologic mechanism of the OP pesticide class.
This statement, in particular, seems 
tailor-made to mislead consumers into
believing that organic foods will protect
against actual neurologic health risks. A pre-
vious article by one of the coauthors pre-
senting similar findings also contains
potentially misleading wording (Curl et al.
2003). In the “Abstract,” Curl et al. (2003)
stated that 
Consumption of organic fruits, vegetables, and
juice can reduce children’s exposure levels from
above to below the U.S. Environmental Protection
Agency’s [EPA] current guidelines, thereby shift-
ing exposures from a range of uncertain risk to a
range of negligible risk.
Collectively, the wording of both papers
strongly implies to consumers and non-
specialists that consuming organic foods
reduces likely or actual harm caused by
residues of OP pesticides. However, evi-
dence of harm from exposure to the low
levels of OP pesticide residues in food is
completely lacking in children or adults.
Although there is some evidence from ani-
mal experiments that in utero exposures to
OP pesticides at high enough doses can
cause neurodevelopmental effects (Eskenazi
et al. 1999), the doses at which such
effects were seen were at least three orders
of magnitude higher than those consumed
as food residues by the children in these two
studies (Curl et al. 2003; Lu et al. 2006).
Recent measurements of OP metabolites
in the U.S. population by two of the authors
of the Lu et al. study (Barr et al. 2005)
allowed estimations of doses at the 95th and
50th percentiles of the population for chlor-
pyrifos (the OP exposure closest to the U.S.
EPA reference dose). Barr et al. (2005) esti-
mated that at the 95th percentile, children
still consumed less than one-half of the U.S.
EPA’s chronic population-adjusted dose
(cPAD), confirming the exposure estimates
used in the risk assessment of the Health
Effects Division at the U.S. EPA in 2000
(Barr et al. 2005). The cPAD for chlorpyri-
fos is 1/1,000th of the no observable adverse
effect level (NOAEL) in dogs and rats.
Thus, children in the 95th percentile con-
sumed < 1/2,000 of the NOAEL, and the
median exposure in children was 1/5,000 of
the NOAEL. 
If it is appropriate to intuitively assume
that organic foods pose a lower probability
of risk to children, is it not also appropriate
to clearly state that all of the risks discussed
in these articles are negligible, given that
they are tiny fractions of the NOAEL in the
most sensitive animal species? It seems that
the language chosen by these authors was
not appropriate. Already, organic food mar-
keting interests are using these articles as
“proof” that organic food is better for you
(Organic Consumers Association 2003); Lu
et al.’s article is even posted on the Organic
Consumers Association website (Organic
Consumers Association 2005).
In the future, those of us who commu-
nicate with the public on food safety issues
should choose our words carefully, not
make claims that go beyond the scope of
the research, and take the time to accurately
place the level of risks being discussed
within the context of what is known from
animal studies.
The author is employed by the Hudson Institute,
a nonprofit organization that has accepted dona-
tions from several chemical and pesticide manu-
facturers over the years, including makers of OP
pesticides. 
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Organic Diets: Lu et al. 
Respond
Avery is concerned that the language used
in our recent article (Lu et al. 2005), as well
as in an earlier article (Curl et al. 2003),
may be used to mislead the public regarding
the relative safety of organic foods com-
pared with foods derived from crops treated
with pesticides. 
We agree that communication of scien-
tific information in general, and health risk
information in particular, requires a careful
choice of words. However, Avery’s analysis
misconstrues the current scientific debate
regarding children’s exposure to pesticides
and misrepresents our work, thereby con-
tributing to the public misunderstanding of
this important issue. 
In fact, we did choose our words care-
fully, and they reflect the essential findings
of our studies. In regard to our earlier publi-
cation (Curl et al. 2003), we provided a
detailed dose estimation to support our con-
clusion that consumption of organic fruits,
vegetables, and juices in the study population
would shift exposure from a range of uncer-
tain risk to a range of negligible risk. In
regard to the more recent study (Lu et al.
2005), our data clearly support the conclu-
sion that organophosphorus (OP) pesticide
exposures are dramatically reduced when
organic foods are substituted for conventional
foods. Our statement that children who
consume organic foods would likely have a
lower probability of neurologic health risks
is consistent with current understandings of
dose–response relationships. In other words,
how could we argue that children with OP
pesticide exposures have the same neurologic
health risks as children whose urine contain
no OP pesticide metabolites?
The assessment of health risks associated
with neurotoxic chemicals such as OP pesti-
cides is a complex analysis that includes sub-
stantial uncertainty. A child may be exposed
to dozens of OP pesticides simultaneously
through the diet, as well as through use of
these pesticides around the home or in
schools. The Food Quality Protection Act
(1996) requires the U.S. Environmental
Protection Agency to evaluate both chil-
dren’s aggregate exposure (multiple exposure
pathways for a single pesticide) and cumula-
tive risk (potential health effects from expo-
sure to multiple compounds that have a
common mechanism of toxicity). Thus, cur-
rent scientific investigations have focused on
the relative contributions of specific exposure
pathways and have attempted to examine
exposure to multiple compounds. Our
recent articles provide new information
regarding the dietary exposure pathway for
several OP pesticides. 
Avery’s criticism of our work by focus-
ing on a single OP pesticide ignores the cen-
tral thrust of the Food Quality Protection
Act (1996), as well as the scientific advances
that have taken place over the past 10 years.
We share Avery’s concern with the judicious
use of language in regard to public commu-
nication of pesticide health risks; all of us—
including Avery—should follow this advice.
The authors declare they have no competing
financial interests.
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Translocation of Ultrafine
Particles 
We read with great interest the article by
Geiser et al. (2005) on the mechanism of
translocation of ultrafine particles (UFPs)
across cellular membranes in vivo in rats fol-
lowing inhalation and in vitro using porcine
pulmonary macrophages and human red
blood cells. 
We are delighted to see this study that
vindicates our hypothesis that translocation
of UFPs is a possible pathway for the cardio-
vascular effects of particulate air pollution. A
few years ago we reported extrapulmonary
translocation of UFPs after intratracheal
instillation in hamsters (Nemmar et al.
2001) and after inhalation in healthy human
volunteers (Nemmar et al. 2002a), suggest-
ing an alternative and/or a complementary
explanation for the extrapulmonary effects
of particles.
In their study, Geiser et al. (2005) very
elegantly provided novel morphologic data
showing the occurrence of translocation of
UFPs, and they also reported—for the first
time—that this translocation did not occur
by endocytic processes but rather by diffu-
sion or adhesive interactions. However, we
noted with some surprise that the authors
cited Brown et al. (2002) when referring to
previous studies on the occurrence of UFP
translocation. Indeed, Brown et al. (2002)
studied the deposition and clearance of an
ultrafine (60 nm) technetium-99m–labeled
aerosol in human volunteers after 2 hr, and
found no significant radioactivity in the liver
(1.3 ± 1.2%). This activity was attributed to
scatter from the lung and/or overlap of lung
parenchyma in the liver. Consequently,
Brown et al. (2002) excluded the occurrence
of translocation and, although they did not
measure radioactivity in blood, they chal-
lenged our conclusion that UFPs (5–10 nm)
could pass from the lungs into blood and
extrapulmonary organs (Nemmar et al.
2002a). Therefore, for the sake of accuracy,
Geiser et al. (2005) should have referred to
our study (Nemmar et al. 2002a) rather
than that of Brown et al. (2002).
Geiser et al. (2005) provided micro-
graphs of fluorescent polystyrene particles
taken up by macrophages (Figure 3) or red
blood cells (Figure 4). It is not clear whether
these polystyrene particles contained surface
charges, for example, carboxylate-modified
(negatively charged) or amine-modified
(positively charged), although Geiser et al.
(2005) briefly discussed the possible effect of
surface charge. This aspect is important; we
(Nemmar et al. 2002b) and others (Silva
et al. 2005) have reported that hemostasis
may be affected by the intravenous or
intratracheal administration of UFPs and
also established that this phenomenon is
dependent on the surface properties of the
particles. Thus, only positively charged
amine-modified particles led to a marked
increase in prothrombotic tendency, which
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In conclusion, although the article by
Geiser et al. (2005) adds a significant amount
of information to the literature related to the
extrapulmonary effect of inhaled particles,
this issue needs to be clarified in more detail.
Therefore, we look forward to this group and
others providing more detailed quantification
of the proportion of inhaled UFPs that can
be found in extrapulmonary organs.
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Ultrafine Particles: Geiser et al.
Respond
Nemmar et al. were surprised that we did
not cite their study in our article (Geiser
et al. 2005) when we referenced state-of-
the-art experiments about the translocation
of ultrafine particles into secondary organs.
We did not cite their human study
(Nemmar et al. 2002) because in Figure 2
of their article, they presented clear evi-
dence that a major fraction of the radio-
labeled technetium-99 (Tc-99m) came off
the Technegas particles. Thus, for method-
ologic reasons, the fraction of translocated
particles could not be determined adequately
and was certainly overestimated by Nemmar
et al. (2002). This was recently discussed by
Kreyling et al. (2004). To briefly illustrate
this, we have included Figure 1. Figure 1A
shows the original whole-body scintigram
published by Nemmar et al. (2002) in which
the salivary glands, the thyroid gland, and
the urinary bladder are clearly visible,
demonstrating that they contain large frac-
tions of the Tc-99m radiolabel. This and the
Tc-99m activity in the soft tissue, which
shows the contour of the whole body, are
clear indications of nonparticulate Tc-99m
in the form of pertechnetate. Pertechnetate
typically accumulates in these organs, as can
be inferred from the Figure 1B, where the
same pattern of radiolabel was detected after
inhalation of soluble Tc-99m pertechnetate. 
In the case of inhalation of nonleaching
Tc-99m radiolabeled ultrafine carbon parti-
cles (Figure 1C), no activity is detectable in
these organs or in the soft tissue. Figure 1C
shows three images taken from the head
(little larynx retention), the thorax (main
carbon particle retention in lungs), and the
lower abdomen, with a rather faint image of
the urinary bladder. A similar pattern has
been reported by Brown et al. (2002).
In addition, Nemmar et al. are interested
in the surface charges of the particles we used
for the in vitro studies, because surface
charges are likely to be important determi-
nants for the translocation of ultrafine parti-
cles as well as for their biologic effects. The
polystyrene particles we used for the studies
with the macrophages and erythrocytes
were either uncharged, amino-modified, or
carboxylate-modified (Rothen-Rutishauser
B, Gehr P, Schürch S, unpublished data).
The surface charges of the gold and titanium
particles are not known. We found non-
phagocytic uptake of ultrafine particles of all
the different materials and surface charges by
macrophages and erythrocytes. However,
because the aim of our study was not to
investigate the effects of surface charges on
cellular uptake, we did not measure the
actual surface charges of the particles or esti-
mate the total number of particles within
cells to quantify particle uptake. We certainly
agree with Nemmar et al. on the importance
of surface charges for particle-cell interaction,
and we hope that we will soon find more
literature published on this aspect.
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Figure 1. (A) Gamma camera image after the inhalation of Tc-99m radiolabeled ultrafine carbon particles not
controlled for leaching. Reproduced from Nemmar et al. (2002) with permission from Lippincott Williams &
Wilkins. (B) Gamma camera image after the inhalation of soluble Tc-99m pertechnetate. Reproduced from
Kreyling et al. (in press) with permission from The Journal of Aerosol Medicine. (C) Gamma camera images
after the inhalation of nonleaching Tc-99m radiolabeled ultrafine carbon particles.REFERENCES
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We read with great interest “Chronic
Beryllium Disease and Sensitization at a
Beryllium Processing Facility” (Rosenman
et al. 2005). We wish to offer some observa-
tions that will broaden the context in which
this article is understood.
I agree with the statement by Rosenman
et al. (2005) that a limitation of the study is
the uncertainty of the exposure estimates. In
addition, many statements appear to be
unsupported by the data provided. For
example, the statement that “most time-
weighted averages were below the
[Occupational Safety and Health
Administration] OSHA (2005) standard of
2 µg/m3” (Rosenman et al. 2005) is unsup-
ported by the data in the tables. Table 11
demonstrates that > 91% of the cohort had
average daily weighted average (DWA) expo-
sures > 2 µg/m3. Table 12 presents only the
highest exposures and shows 56% of the
cohort members having exposures > 2 µg/m3
and all but two cohort members exposed to
> 0.2 µg/m3. Rosenman et al. (2005) did not
explain how the average exposures of the
cohort exceed 2 µg/m3 at a rate greater than
the peak exposures. This same mysterious
artifact of average exposures exceeding peak
exposures is also present in Tables 9 and 10.
The exposure-estimating process used by
these authors could have introduced an
erroneous bias in the data set, which causes
me to question the “Discussion” and the
conclusions drawn from the data.
One point, unstated by Rosenman et al.
(2005), is that the DWA represented the
daily exposure based on data averaged over
3 months. This is not the same as taking a
single 8-hr air sample on 1 day because the
3-month averaging of the task data does not
reveal the daily up and down variation in
the individual task sample results. The
National Institute for Occupational Safety
and Health (NIOSH) has found DWAs
not comparable to the lapel sampling
method used by OSHA to determine com-
pliance with its permissible exposure limit
(PEL) or other 8-hr occupational exposure
limits (OELs) (Donaldson and Stringer
1976). In addition, the average exposures
presented by Rosenman et al. (2005) in
their tables are the result of a second averag-
ing by whole year and finally a third averag-
ing by years of work. Such triple averaging
further reduces the standard deviation in
the data set, which results in a failure to
identify the true high and low ranges of
daily exposure. The American Industrial
Hygiene Association (AIHA) exposure
assessment guide (Mulhausen and Damiano
1998) cautions against ignoring air sample
results that comprise the upper tail of an
individual’s exposure distribution, especially
when comparing it to PELs and OELs. 
The flame spectroscopy method of
chemical analysis of beryllium used by
Rosenman et al. (2005) during the data-
collection period of this study had a detec-
tion limit of 0.1 µg/filter that translates to
< 0.1 µg/m3 for any lower value. Therefore,
Rosenman et al. (2005) cannot make any
statements about exposures lower than this
value.
Rosenman et al.’s (2005) description of
missing and estimated data, the illogical
peak versus average data results, the triple
averaged DWA exposure estimates, and the
limit of analytical detection of the sampling
method all combine to make it likely that
virtually all members of the study popula-
tion experienced multiple days of exposure
>2µ g / m 3, and hence the study cannot sus-
tain conclusions about the degree of risk
associated with lower levels of exposure.
This conclusion is supported by the obser-
vation that the rates of chronic beryllium
disease (CBD) and sensitization were con-
stant across all the categories of exposure
used by Rosenman et al. (2005). 
Rosenman et al. (2005) made no recom-
mendations regarding how to protect beryl-
lium workers. We cannot change the past,
but we can learn from it and change the
future. There are two successful models of
beryllium safety: one demonstrates effective-
ness in preventing clinical CBD (Johnson
et al. 2001), and one demonstrates preven-
tion of beryllium sensitization (BeS) using
the beryllium blood lymphocyte prolifera-
tion test as an index of BeS (Cummings K,
unpublished data). Common to both models
are a) organization and cleanliness of the
workplace; b) control of the upper range of
air level exposure using engineering and res-
piratory protection; c) control of beryllium
migration from the work process to the
worker, the work area, and outside the facil-
ity; d) detailed training of workers; and
e) management and worker commitment to
effective program implementation. In the
facility studied by Rosenman et al. (2005), it
is not clear that any of the above elements of
a beryllium safety management plan were
consistently accomplished. Although this is
understandable, given prevalent scientific
opinion at the time, going forward we
should make every effort to effectively dis-
seminate these demonstrated beryllium safety
principles to the companies and workers
using beryllium.
The author is employed by Brush Wellman
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Beryllium Exposure Data:
Rosenman et al. Respond
We thank Kolanz for his careful reading of
our article (Rosenman et al. 2005). An erra-
tum correcting the problem he noted
appears on page A214. 
How do these corrected numbers change
our results? More chronic beryllium disease
(CBD) and sensitization occurred with
exposure below the Occupational Safety and
Health Administration (OSHA) permissible
exposure limit (PEL) of 2 µg/m3 (OSHA
2005) than we previously reported, but no
CBD or sensitization was found below the
Department of Energy (DOE) guidelines of
0.2 µg/m3 (DOE 1999) or the even more
protective level proposed by the American
Conference of Governmental Industrial
Hygienists (ACGIH 2005) of 0.02 µg/m3.
There was an insufficient number of indi-
viduals—only three, and they were all nor-
mal—to assess the safety of the DOE
guidelines or proposed ACGIH level. Our
previously reported findings regarding
chemical and physical form—that sensitized
individuals compared with individuals with
CBD had higher exposure to beryllium in a






soluble form and to fumes of beryllium
(Rosenman et al. 2005)—remain unchanged.
However, the mean peak exposure for the
sensitized group in our Table 8, the mean
nonsoluble exposure for the sensitized group
in Table 9, and the mean dust exposure for
the sensitized group and mean fume expo-
sure for the CBD group in Table 10 were
no longer significantly different, whereas the
peak fume exposure for the CBD group was
now significantly different in Table 10.
Having acknowledged and corrected the
error pointed out by Kolanz, we take strong
exception to his statement that “the study
cannot sustain conclusions about the degree
of risk associated with lower levels of expo-
sure,” by which he means less than the
OSHA PEL of 2 µg/m3 (OSHA 2005). 
One of Kolanz’s criticisms of our article
(Rosenman et al. 2005) is that the daily
weighted average (DWA) represented the
daily exposure based on data averaged over
3 months. Breslin and Harris (1958) con-
ducted a time study, which was updated as
activities and location changed for each job
title. During a 3-month period, three or
more samples were collected and standard-
ized to represent the general area where
each person worked, and in some cases the
breathing zone during work activities. The
arithmetic average of the samples for each
location/type was then calculated and
weighted by time (Breslin and Harris 1958).
Use of these summed weighted values,
divided by the shift duration, is consistent
with the American Industrial Hygiene
Association (AIHA) exposure assessment
guidance (Mulhausen and Damiano 1998)
cited by Kolanz.
We agree with Kolanz’s comment about
the use of the flame spectroscopy method of
chemical analysis and its general limit of
detection of 0.1 µg/m3. In the job exposure
matrix and task exposure matrix developed
to support this project (Chen 2001), no
exposure estimate was < 0.1 µg/m3, so this
issue would have no effect on our results.
Kolanz also takes exception with our
estimates of mean exposures, stating that
these values were derived by triple averaging.
We derived the mean exposures as follows:
for a given worker in a given job in a given
year, we multiplied the number of days
worked in that year for that worker by our
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In the article by Rosenman et al. [Environ Health Perspect 113:1366–1372 (2005)], the authors noted errors in Tables 8–11, which
resulted from a programming error. Because of this error, the overall mean daily weighted averages (DWAs) were greater than they should
have been. The corrected tables are shown below. 
The correct mean exposure levels for the DWA categories in Table 11 were 0.13, 1.15, and 3.13 µg/m3.
Table 8. Development of definite/probable CBD and sensitization by average cumulative, average mean, and peak exposure (± SE).
Disease  No. of Mean cumulative  Mean exposure Mean average  Mean peak exposure
outcome individuals exposure (µg-year/m3) (days) exposure (mg/m3) (mg/m3)
Definite/Probable CBD 40 181 ± 29 3483 ±50 1.6 ± 0.21 3.1 ± 0.36
Sensitization 37 100 ± 23a 1934 ±5b 1.6 ± 0.16 2.9 ± 0.4 
Normal 377 209 ± 16 3359 ±76 1.6 ± 0.06 3.3 ± 0.13
ap = 0.03 for sensitization vs. definite/probable and p = 0.0003 for sensitization vs. normal. bp = 0.047 for sensitization vs. definite/probable and p = 0.02 for sensitization vs. normal.
Table 9. Development of definite/probable CBD and sensitization by chemical form of beryllium, mixed, nonsoluble, and soluble: mean cumulative, mean
average, and mean peak exposure levels.
Mixed Nonsoluble Soluble
Cumulative Mean Peak Cumulative Mean Peak Cumulative Mean Peak
Disease outcome No. (µg-year/m3) (µg/m3) (µg/m3) (µg-year/m3) (µg/m3) (µg/m3) (µg-year/m3) (µg/m3) (µg/m3)
Definite/probable CBD 40 50 0.9 3.7 126 1.7 5.1 5.8a 0.9 1.1
Sensitization 37 20b 0.8 6.8 61c 1.6 5.1 19 0.8 3.3
Normal 377 49 0.9 5.9 128 1.6 6.1 26 0.9 2.7
ap < 0.0001 for definite/probable vs. normal. bp = 0.0005 for sensitization vs. normal. cp = 0.04 for sensitization vs. definite/probable, and p = 0.003 for sensitization vs. normal.
Table 11. Development of definite/probable CBD and sensitization by the American Conference of Governmental
and Industrial Hygienists notice of intended change, current OSHA, and DOE DWA threshold levels.
Mean DWA exposure (µg/m3) [n (%)]
Disease outcome 0 to < 0.02 0.02 to < 0.2 0.2 to < 2 ≥ 2
Definite/probable CBD 0 (0) 0 (0) 33 (10) 7 (6)
Sensitization 0 (0) 0 (0) 24 (7) 13 (11)
Normal 0 (0) 3 (100) 279 (83) 95 (83)
Table 10. Development of definite/probable CBD and sensitization by physical form of beryllium, dust, fume, and mixed: mean cumulative, mean average,
and mean peak exposure levels.
Dust Fume Mixed
Cumulative Mean Peak Cumulative Mean Peak Cumulative Mean Peak
Disease outcome No. (µg-year/m3) (µg/m3) (µg/m3) (µg-year/m3) (µg/m3) (µg/m3) (µg-year/m3) (µg/m3) (µg/m3)
Definite/probable CBD 40 128 1.6 5.2 4a 0.5 0.8b 49 0.9 3.7
Sensitization 37 66c 1.5 5.1 17 0.9 3.3 17d 0.8 6.8
Normal 377 138 1.5 6.6 20 0.6 1.9 46 0.9 5.9
ap = 0.0002 for definite/probable vs. normal. bp = 0.04 for definite/probable vs. normal. cp = 0.0021 for sensitization vs. normal. dp = 0.0004 for sensitization vs. normal.best estimated DWA for that job in that
year. We then summed those values over all
jobs for that worker to derive that worker’s
cumulative exposure. Next we divided that
worker’s cumulative exposure by the total
number of days worked in his/her job history
to derive that worker’s mean exposure. Thus,
there is only one averaging on each worker
and a subsequent averaging for the popula-
tion. We used multiple metrics (cumulative,
average, peak job, and peak task for total
exposure; exposure by chemical form; and
exposure by physical form) to characterize
not only the central tendencies of the expo-
sures but also their extreme excursions.
We stand by our statement that 
The inclusion of genetic data combined with
exposure data may better define which individuals
in this cohort are at a particularly high risk of
development of CBD and/or sensitization and
may account for the absence of typical exposure–
response seen with other environmental or occu-
pational toxins.
It is also important to note that both peak
exposure and the different chemical and
physical forms may be important factors in
the risk of development of CBD but are not
part of the current OSHA standard (OSHA
2005). 
Finally, Kolanz states that “Rosenman
et al. (2005) made no recommendations
regarding how to protect beryllium workers.”
Clearly, however, our call to lower the
allowable standard is a recommendation we
put forth to protect beryllium workers.
Despite the limitations of deriving historical
exposure estimates, our corrected data con-
tinue to point to the inadequacy of the cur-
rent OSHA standard to protect workers
from developing chronic beryllium disease.
M.R. has served as an expert witness both for
companies and for workers; he evaluates indus-
trial patients with CBD, serves as the director of
a beryllium test laboratory, and is a principal
investigator with a grant from Los Alamos. The
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